News & Events

Upcoming Events

Tue, 7/5/2022 - 12:00 PM ET
For patients/survivors Join us every Tuesday for this general meetup… more
Fri, 7/8/2022 - 6:30 PM ET
For patients/survivors General meetup moderated by survivors… more
Tue, 7/12/2022 - 12:00 PM ET
For patients/survivors Join us every Tuesday for this general meetup… more
Fri, 7/15/2022 - 9:00 AM ET
The International Lung Cancer Survivorship Conference (ILCSC) is a… more
Fri, 7/15/2022 - 6:30 PM ET
For patients/survivors General meetup moderated by survivors… more
June 2, 2022

We're Live-Tweeting from ASCO June 3-7!

June 2, 2022

We're Live-Tweeting from ASCO June 3-7!

LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows: Fri, Jun 3, 2022 | 2:00 PM – 5:00 PM EDT | Lung Cancer—Non-Small Cell Metastatic  Sun, Jun 5, 2022 | 9:00 AM – 10:15 AM EDT | Treatment Sequencing in Resectable Lung Cancer…
April 28, 2022

New Options in Adjuvant Therapy for Early-Stage NSCLC

April 28, 2022

New Options in Adjuvant Therapy for Early-Stage NSCLC

Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…
April 26, 2022

Highlights of the 2022 AACR meeting

April 26, 2022

Highlights of the 2022 AACR meeting

The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss…
April 22, 2022

KRAS: How It Started vs. How It’s Going

April 22, 2022

KRAS: How It Started vs. How It’s Going

On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since the KRAS oncogene was discovered 40 years ago. KRAS is a leading driver mutation in various forms of cancer. Still, targeting KRAS had failed for nearly four decades, leading many to believe that it was “…
April 19, 2022

Immunotherapy in Early-Stage Lung Cancer

April 19, 2022

Immunotherapy in Early-Stage Lung Cancer

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, interviews Patrick Forde, MD (MB, BCh), at the 2022 AACR meeting (April 12, 2022).